Singapore markets closed
Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,466.83 -2.47 (-0.05%) Dow
38,967.84 -144.32 (-0.37%) Nasdaq
17,772.04 +54.38 (+0.31%) Bitcoin USD
61,927.39 +529.15 (+0.86%) CMC Crypto 200
1,280.46 -3.32 (-0.26%)
ITCI Dec 2024 65.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:53PM EDT. Market open.
| Previous close | 3.2000 |
| Open | 3.4000 |
| Bid | 3.8000 |
| Ask | 5.1000 |
| Strike | 65.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.2000 - 3.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 119 |
ZacksIntra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
ZacksBiotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
ZacksIntra-Cellular (ITCI) Up as Second Depression Study Meets Goals
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
© 2024 Yahoo. All rights reserved.